Baktiar Hasan

3.0k total citations · 1 hit paper
45 papers, 1.8k citations indexed

About

Baktiar Hasan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Baktiar Hasan has authored 45 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 9 papers in Epidemiology. Recurrent topics in Baktiar Hasan's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (11 papers). Baktiar Hasan is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (11 papers). Baktiar Hasan collaborates with scholars based in Belgium, Netherlands and United Kingdom. Baktiar Hasan's co-authors include John J. Welch, Benjamin Besse, Jan P. van Meerbeeck, Jessica Menis, Lesley Seymour, Keyue Ding, Frances A. Shepherd, Rabab Gaafar, Paul Baas and Murielle Mauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Baktiar Hasan

45 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954

2010 507 citations Murielle Mauer, Baktiar Hasan et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Baktiar Hasan

Since Specialization

Citations

This map shows the geographic impact of Baktiar Hasan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baktiar Hasan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baktiar Hasan more than expected).

Fields of papers citing papers by Baktiar Hasan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baktiar Hasan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baktiar Hasan. The network helps show where Baktiar Hasan may publish in the future.

Co-authorship network of co-authors of Baktiar Hasan

This figure shows the co-authorship network connecting the top 25 collaborators of Baktiar Hasan. A scholar is included among the top collaborators of Baktiar Hasan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baktiar Hasan. Baktiar Hasan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982) 2020 ·Annals of Oncology ·K. Newbold, (unknown), Baktiar Hasan, Laura D. Locati, Yann Godbert, Christelle de la Fouchardière, Lars Bastholt, Martin Faßnacht, Nicole Reed, Yassine Lalami, C. Chougnet, Claire Schvartz, Ellen Kapiteijn, M Schlumberger, Ward Sents, Nicolas Sauvé, Sophie Leboulleux	1
2	LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer 2020 ·Annals of Oncology ·Benjamin Besse, Jessica Menis, Paolo Bironzo, R. Gervais, Laurent Greillier, I. Monnet, Lorenzo Livi, Robyn R. Young, C. Decroisette, Nicolas Cloarec, G. Robinet, Roland Schött, Raffaele Califano, Filippo de Marinis, Giuseppe Luigi Banna, Murielle Mauer, (unknown), Baktiar Hasan, Thierry Berghmans, Anne‐Marie C. Dingemans	18
3	Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review 2019 ·Journal of Thoracic Oncology ·Niccolò Giaj‐Levra, Matteo Giaj Levra, Valérie Durieux, Silvia Novello, Benjamin Besse, Baktiar Hasan, Lizza Hendriks, Antonin Lévy, Anne‐Marie C. Dingemans, Thierry Berghmans	38
4	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey 2019 ·Lung Cancer ·Antonin Lévy, Lizza Hendriks, C. Le Péchoux, (unknown), Benjamin Besse, Silvia Novello, Anne‐Marie C. Dingemans, Baktiar Hasan, Martin Reck, Thierry Berghmans, Corinne Faivre‐Finn	21
5	Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion 2019 ·European Journal of Cancer ·Lizza Hendriks, Christophe Dooms, Thierry Berghmans, Silvia Novello, Antonin Lévy, Dirk De Ruysscher, Baktiar Hasan, Matteo Giaj Levra, Niccolò Giaj‐Levra, Benjamin Besse, Johan Vansteenkiste, Anne‐Marie C. Dingemans	16
6	MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC 2018 ·Journal of Thoracic Oncology ·Antonin Lévy, Lizza Hendriks, Thierry Berghmans, Corinne Faivre‐Finn, Matteo Giaj Levra, Niccolò Giaj‐Levra, Baktiar Hasan, Nicolas Girard, Laurent Greillier, Sylvie Lantuéjoul, John Edwards, Mary O’Brien, Martin Reck, Benjamin Besse, Silvia Novello, Anne‐Marie C. Dingemans	3
7	MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion 2018 ·Journal of Thoracic Oncology ·Lizza Hendriks, Christophe Dooms, Thierry Berghmans, Silvia Novello, Antonin Lévy, Dirk De Ruysscher, Baktiar Hasan, Matteo Giaj Levra, Niccolò Giaj‐Levra, Benjamin Besse, Johan Vansteenkiste, Anne‐Marie C. Dingemans	2
8	Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer 2018 ·The Pharmacogenomics Journal ·(unknown), Chara Papadaki, (unknown), Eleni Lagoudaki, Jessica Menis, Anastasios Koutsopoulos, Maria Trypaki, (unknown), Maria Sfakianaki, Baktiar Hasan, E. Stathopoulos, Vassilis Georgoulias, John Souglakos	5
9	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey 2018 ·European Journal of Cancer ·Antonin Lévy, Corinne Faivre‐Finn, Baktiar Hasan, (unknown), Anna S. Berghoff, Nicolas Girard, Laurent Greillier, Sylvie Lantuéjoul, Mary O’Brien, Martin Reck, Anne‐Marie C. Dingemans, Silvia Novello, Thierry Berghmans, Benjamin Besse, Lizza Hendriks	59
10	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS) 2017 ·Annals of Oncology ·Luis Paz‐Ares, Baktiar Hasan, Urania Dafni, Jessica Menis, (unknown), Kersti Oselin, István Albert, Martin Faehling, Paul Van Schil, Mary O’Brien	8
11	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613 2017 ·Clinical Lung Cancer ·Jordi Remón, Jessica Menis, Baktiar Hasan, Aleksandra Peric, (unknown), Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasąg, Benjamin Besse, Rafał Dziadziuszko	77
12	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: A single-arm phase II study (EORTC-08061) 2015 ·European Journal of Cancer ·(unknown), Egbert F. Smit, Baktiar Hasan, Jessica Menis, Sanjay Popat, Jan P. van Meerbeeck, Veerle Surmont, Paul Baas, Mary O’Brien	18
13	Progression free survival rate at 9 and 18weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation 2014 ·European Journal of Cancer ·Baktiar Hasan, Laurent Greillier, Athanasios Pallis, Jessica Menis, Rabab Gaafar, Richard Sylvester, Dean A. Fennell, Paul Baas, Veerle Surmont, Jan P. van Meerbeeck, Mary O’Brien	8
14	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response 2014 ·European Respiratory Review ·Jessica Menis, Baktiar Hasan, Benjamin Besse	63
15	Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012 2012 ·Journal of Clinical Oncology ·Reinhard Dummer, Pietro Quaglino, Jürgen C. Becker, Baktiar Hasan, Matthias Karrasch, Sean Whittaker, Stephen Morris, Michael Weichenthal, Rudolf Stadler, M. Bagot, Antonio Cozzio, Maria Grazia Bernengo, Robert Knobler	70
16	High prevalence of osteoblastic bone reaction in computed tomography scans of an European Organisation for Research and Treatment of Cancer prospective randomised phase II trial in extensive stage small cell lung cancer 2012 ·European Journal of Cancer ·Christian Fink, Baktiar Hasan, (unknown), Athanasios Pallis, Paul Baas, (unknown)	5
17	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062 2011 ·European Journal of Cancer ·Mary O’Brien, (unknown), Paul Lorigan, Lionel Bosquée, Ernest Marshall, F. Bustin, (unknown), Christian Fink, Jos A. Stigt, Anne‐Marie C. Dingemans, Baktiar Hasan, Jan P. van Meerbeeck, Paul Baas	21
18	Venous thromboembolism and nonsmall cell lung cancer 2009 ·Cancer ·Lisa K. Hicks, Matthew C. Cheung, Keyue Ding, Baktiar Hasan, Lesley Seymour, Aurélie Le Maître, Natasha B. Leighl, Frances A. Shepherd	54
19	Biomarkers for Malignant Pleural Mesothelioma 2008 ·Molecular Diagnosis & Therapy ·Laurent Greillier, Paul Baas, John J. Welch, Baktiar Hasan, A. Passioukov	43
20	A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 2008 ·Journal of Thoracic Oncology ·Marie Florescu, Baktiar Hasan, Lesley Seymour, Keyue Ding, Frances A. Shepherd	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact